
Creating a world without cancer
Defeating cancer using virus biology
We are developing next-generation oncolytic virus immunotherapies designed to selectively destroy cancer cells while directing the body's natural defenses against cancer.
Our proprietary patented platform leverages a novel modified vaccinia virus (VACV) designed to exploit cancer cells' deficiencies in cell death programs, delivering exceptional selectivity and maximum destruction of cancer cells.
Be a part of the impact.
A new era for Oncolytic Virus therapy
WHY
Transforming lives
Envision a future where cancer is no longer a devastating threat, but a manageable condition without adverse events. Our oncolytic virus immunotherapy platform has the potential to transform the cancer treatment landscape and offer new hope to millions of patients.
“Our OV platform is derived from exploiting infection biology.”
– Prof. Ian Mohr, NYU School of Medicine
Current cancer treatments like radiation, chemotherapy, and surgery often lack precision, affecting both healthy and cancerous cells, leading to significant side effects and limited effectiveness in advanced or resistant cancers.
Omios OV therapy addresses the limitations of current therapies by selectively targeting metastases, and offering improved tolerability, resistance-free treatment, and lasting results to prevent relapse.
Help lead the way in driving breakthroughs
“
Cancer's complexity demands sophisticated therapies”
– Aldo Pourchet Founder and CEO
HOW
Revolutionizing cancer treatment by harnessing the power of viruses
Our innovative approach is based on a deep understanding of the complex interplay between viruses and human cells, both healthy and cancerous. We have engineered a novel vaccinia virus that offers a safe, effective, and versatile platform for treating a wide range of solid tumors.
A new way to design
oncolytic viruses
A paradigm shift
While previous approaches relied on attenuation for safety and to the detriment of efficacy, we've engineered a more selective solution. Our modified vaccinia viruses are designed to replicate only in the presence of specific cancer mutations in cell death programs; a hallmark of cancer cells.
This innovative approach enhances the viruses' ability to selectively target and destroy cancer cells while stimulating a potent anti-tumor immune response. As the first oncolytic virus platform with a built-in biomarker, Omios Bio provides a solid foundation for building the next generation of cancer immunotherapy.
Be a catalyst for the future of cancer research.
A technological revolution patented by pioneers
Vaccinia virus
Historically a benign virus used to create the first vaccine to eradicate smallpox, the only viral disease eradicated to date.
Omios' modified vaccinia virus
Engineered for safety and maximum efficacy against cancer. By deleting specific viral genes (e.g E3L, D10), we've generated safe vectors with exceptional cancer selectivity. We've also added therapeutic genes to further increase cancer killing activity and boost the anti-cancer immune response.

Here’s how it works
Technology Platform

1.
Omios Oncolytic Virus (OV) platform leverages a biomarker to treat patients sooner and better

2.
Systemic intravenous delivery

3.
Selectively target the tumor

4.
Maximum lytic activity for a durable impact on cancer

5.
Combination with standard of care

6.
No added toxicity
Be a catalyst for the future of cancer research.
THE PLAN
Our path forward
We are developing life-changing cancer therapies that are accessible to patients worldwide at any stage of their journey.
We began our journey focusing on breast, liver, and colon cancers. Over 5.3 million patients are diagnosed globally with these three cancers each year. It is projected that the global economic burden between 2020–2050 from these 3 cancers is an estimated 6.6 trillion dollars in treatment.

Our technology pipeline focuses on developing safe and selective oncolytic vaccinia viruses that can combine with standard of care.
Our 3 programs
Oncolytic Virus therapy
Uses Oncolytic Virus platform based on a newly patented vaccinia virus.
Vaccine platform for cancer + infectious diseases
Uses a modified vaccinia virus to create vaccines for cancer and infectious diseases.
Gene Delivery platform
Uses a modified vaccinia virus for systemic gene delivery to treat solid tumors.
THE TEAM
Over 80 years of expertise in Oncolytic Virus development and manufacturing
The team
The Omios founding team brings together a unique blend of deep scientific expertise in oncolytic virotherapy, successful biotech entrepreneurship, and proven business acumen. We are dedicated to applying the highest standards of scientific rigor to bring our therapies to patients.
Omios Bio Advisors
Our advisors are world-renowned virologists, immunologists, and experienced biotech executives with a proven track record in oncolytic virus development, regulatory affairs, and successful commercialization of cancer therapies. They provide critical guidance in poxvirus engineering, clinical trial design, GMP manufacturing, and business strategy, ensuring the successful translation of Omios's cutting-edge science into impactful cancer treatments.

Julie M Cherrington, PhD
Biotechnology Executive, Board Chair/Member, Advisor
Formerly President, CEO and board member of QUE Oncology, Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics.

Leonard Post, PhD
Biotech industry advisor and board member. Former CSO of Vivace, BioMarin, Onyx.

Laurent Coscoy, PhD
Professor of Immunology and Molecular Medicine
UC Berkeley Department of Molecular & Cell Biology

Brian Ruffell, PhD
Department of Immunology
H. Lee Moffitt Cancer Center

Laurence Nore, MBA
Executive Vice-President, Business Development and operation at IgGenix